Redhill Biopharma Ltd (RDHL) - Net Assets
Based on the latest financial reports, Redhill Biopharma Ltd (RDHL) has net assets worth $4.27 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.34 Million) and total liabilities ($21.08 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how tangible is Redhill Biopharma Ltd's equity to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $4.27 Million |
| % of Total Assets | 16.84% |
| Annual Growth Rate | N/A |
| 5-Year Change | -51.91% |
| 10-Year Change | -93.19% |
| Growth Volatility | 204.62 |
Redhill Biopharma Ltd - Net Assets Trend (2010–2025)
This chart illustrates how Redhill Biopharma Ltd's net assets have evolved over time, based on quarterly financial data. See how many days can Redhill Biopharma Ltd fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Redhill Biopharma Ltd (2010–2025)
The table below shows the annual net assets of Redhill Biopharma Ltd from 2010 to 2025. For live valuation and market cap data, see RDHL company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $4.27 Million | +191.14% |
| 2024-12-31 | $-4.68 Million | -326.34% |
| 2023-12-31 | $2.07 Million | +104.27% |
| 2022-12-31 | $-48.40 Million | -645.35% |
| 2021-12-31 | $8.88 Million | -35.99% |
| 2020-12-31 | $13.86 Million | -76.89% |
| 2019-12-31 | $60.00 Million | +17.22% |
| 2018-12-31 | $51.19 Million | +13.58% |
| 2017-12-31 | $45.06 Million | -28.13% |
| 2016-12-31 | $62.70 Million | +4.37% |
| 2015-12-31 | $60.08 Million | +140.20% |
| 2014-12-31 | $25.01 Million | +109.74% |
| 2013-12-31 | $11.93 Million | -37.30% |
| 2012-12-31 | $19.02 Million | +1.23% |
| 2011-12-31 | $18.79 Million | +1278.61% |
| 2010-12-31 | $-1.59 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Redhill Biopharma Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41375500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $147.64 Million | 3459.25% |
| Other Components | $270.38 Million | 6335.10% |
| Total Equity | $4.27 Million | 100.00% |
Redhill Biopharma Ltd Competitors by Market Cap
The table below lists competitors of Redhill Biopharma Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
BGT Corporation Public Company Limited
BK:BGT
|
$4.08 Million |
|
Riedel Resources Ltd
AU:RIE
|
$4.08 Million |
|
Nordic Asia Investment Group 1987 AB Series B
ST:NAIG-B
|
$4.09 Million |
|
Matinas BioPharma Holdings Inc
NYSE MKT:MTNB
|
$4.09 Million |
|
Falmaco Nonwoven Industri PT Tbk
JK:FLMC
|
$4.07 Million |
|
Aquaporin AS
CO:AQP
|
$4.07 Million |
|
Whitehawk Ltd
AU:WHK
|
$4.06 Million |
|
Spartoo SAS
PA:ALSPT
|
$4.06 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Redhill Biopharma Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -4,683,000 to 4,268,000, a change of 8,951,000.
- Net loss of 429,000 reduced equity.
- New share issuances of 7,764,000 increased equity.
- Other factors increased equity by 1,616,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-429.00K | -10.05% |
| Share Issuances | $7.76 Million | +181.91% |
| Other Changes | $1.62 Million | +37.86% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Redhill Biopharma Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.58x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-12-31 | $-154.71 | $0.79 | x |
| 2011-12-31 | $1953.52 | $0.79 | x |
| 2012-12-31 | $1807.97 | $0.79 | x |
| 2013-12-31 | $955.91 | $0.79 | x |
| 2014-12-31 | $1433.79 | $0.79 | x |
| 2015-12-31 | $2688.97 | $0.79 | x |
| 2016-12-31 | $2434.05 | $0.79 | x |
| 2017-12-31 | $1276.12 | $0.79 | x |
| 2018-12-31 | $1106.96 | $0.79 | x |
| 2019-12-31 | $1010.41 | $0.79 | x |
| 2020-12-31 | $190.30 | $0.79 | x |
| 2021-12-31 | $95.37 | $0.79 | x |
| 2022-12-31 | $-390.77 | $0.79 | x |
| 2023-12-31 | $3.99 | $0.79 | x |
| 2024-12-31 | $-1.90 | $0.79 | x |
| 2025-12-31 | $1.35 | $0.79 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Redhill Biopharma Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -150.00%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 5.94x
- Recent ROE (-10.05%) is above the historical average (-68.94%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.38 Million |
| 2011 | -82.52% | -67404.35% | 0.00x | 1.07x | $-17.38 Million |
| 2012 | -54.30% | -64537.50% | 0.00x | 1.06x | $-12.23 Million |
| 2013 | -89.12% | -88566.67% | 0.00x | 1.20x | $-11.82 Million |
| 2014 | -42.83% | -152.71% | 0.24x | 1.15x | $-13.21 Million |
| 2015 | -35.10% | -703000.00% | 0.00x | 1.11x | $-27.10 Million |
| 2016 | -46.84% | -29079.21% | 0.00x | 1.18x | $-35.64 Million |
| 2017 | -101.06% | -1136.61% | 0.07x | 1.27x | $-50.05 Million |
| 2018 | -75.84% | -464.35% | 0.13x | 1.22x | $-43.94 Million |
| 2019 | -70.50% | -672.45% | 0.08x | 1.23x | $-48.30 Million |
| 2020 | -549.43% | -118.36% | 0.36x | 13.00x | $-77.56 Million |
| 2021 | -1101.34% | -113.98% | 0.47x | 20.42x | $-98.63 Million |
| 2022 | 0.00% | -115.97% | 0.39x | 0.00x | $-66.83 Million |
| 2023 | 1155.91% | 366.25% | 0.28x | 11.14x | $23.71 Million |
| 2024 | 0.00% | -102.80% | 0.45x | 0.00x | $-7.80 Million |
| 2025 | -10.05% | -150.00% | 0.01x | 5.94x | $-855.80K |
Industry Comparison
This section compares Redhill Biopharma Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $379,169,986
- Average return on equity (ROE) among peers: -14.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Redhill Biopharma Ltd (RDHL) | $4.27 Million | 0.00% | 4.94x | $4.08 Million |
| Aurora Cannabis Inc (ACB) | $521.74 Million | -156.52% | 0.78x | $172.65 Million |
| Akanda Corp (AKAN) | $-11.99 Million | 0.00% | 0.00x | $7.56 Million |
| Akebia Ther (AKBA) | $635.93 Million | -27.03% | 0.57x | $273.24 Million |
| Alkermes Plc (ALKS) | $1.21 Billion | -17.23% | 0.43x | $7.42 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $433.43 Million | 11.37% | 0.19x | $1.64 Billion |
| Amphastar P (AMPH) | $445.52 Million | 13.94% | 0.51x | $854.96 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $-44.54 Million | 0.00% | 0.00x | $5.19 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $366.97 Million | 2.90% | 9.74x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $37.89 Million | 15.55% | 0.65x | $189.34 Million |
| ANI Pharmaceuticals Inc (ANIP) | $197.26 Million | 7.85% | 1.18x | $1.80 Billion |
About Redhill Biopharma Ltd
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company develops and commercializes Talicia for the treatment of H. pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its pipeline consists of five therapeutic candidates, which are in clinical development include opaganib for … Read more